This page has only limited features, please log in for full access.

Unclaimed
Niels Abildgaard
Quality of Life Research Center, Department of Haematology, Odense University Hospital, 5000 Odense C, Denmark

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 27 August 2021 in COVID
Reads 0
Downloads 0

In general, governments and health authorities have taken precautions during the COVID-19 pandemic to reduce the viral spread and protect vulnerable citizens. Patients with multiple myeloma (MM) have an increased risk of being infected with COVID-19 and developing a fatal course due to the related immunodeficiency. We investigated how Danish patients with MM reported their quality of life (QoL) pre-COVID and during COVID, in an ongoing longitudinal QoL survey. The responses given during the first and second wave of the COVID-19 pandemic were pooled, analyzed and compared to the same period the year before. We hypothesized that locking down the society would have caused deteriorated QoL and that patients living alone and those under the age of 65 would be particularly affected by the situation. Surprisingly, our study showed the opposite. Statistically significant and clinically relevant differences were primarily found during the first lock down and represented reduced fatigue, improved role functioning, decreased insomnia and improved physical health summaries in patients below 65 years of age. These results indicate that Danish patients with MM might have felt protected and safe by COVID restrictions. Otherwise, the questionaries used in QoL-MM survey may not have been able to capture the impact of the COVID-19 pandemic. Importantly, this indicates that QoL survey data obtained in clinical studies, in countries with highly developed health-care systems using standard questionnaires during the pandemic, allow room for interpretation without being adjusted for the impacts of the pandemic.

ACS Style

Louise Redder; Sören Möller; Anna Thit Johnsen; Mary Jarden; Christen Lykkegaard Andersen; Bo Amdi Jensen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard; Lene Kongsgaard Nielsen. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. COVID 2021, 1, 303 -314.

AMA Style

Louise Redder, Sören Möller, Anna Thit Johnsen, Mary Jarden, Christen Lykkegaard Andersen, Bo Amdi Jensen, Henrik Frederiksen, Henrik Gregersen, Anja Klostergaard, Morten Saaby Steffensen, Per Trøllund Pedersen, Maja Hinge, Mikael Frederiksen, Carsten Helleberg, Anne Kærsgaard Mylin, Niels Abildgaard, Lene Kongsgaard Nielsen. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. COVID. 2021; 1 (1):303-314.

Chicago/Turabian Style

Louise Redder; Sören Möller; Anna Thit Johnsen; Mary Jarden; Christen Lykkegaard Andersen; Bo Amdi Jensen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard; Lene Kongsgaard Nielsen. 2021. "Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic." COVID 1, no. 1: 303-314.

Communication
Published: 15 June 2021 in Molecules
Reads 0
Downloads 0

Screening for systemic amyloidosis is typically carried out with abdominal fat aspirates with varying reported sensitivities. Fat aspirates are preferred for use in primary screening instead of organ biopsies as they are less invasive and thereby minimize the potential risk of complications. At Odense Amyloidosis Center, we performed a prospective study on whether the combined use of fat aspirate and tru-cut skin biopsy could increase the diagnostic sensitivity. Both fat aspirates and skin biopsies were screened with Congo Red staining, and positive biopsies were subsequently subtyped using immunoelectron microscopy and mass spectrometry. Seventy-six patients were included. In total, 24 patients had systemic amyloidosis (11 AL, 12 wtATTR, 1 AA), and 6 patients had localized amyloidosis. Combined fat aspirate and skin biopsy were Congo Red-positive in 15 patients (overall sensitivity (OS) 62.5%). Fat aspirates were positive in 14 patients (OS 58.3%), and the skin biopsy was positive in 5 patients (OS 20.8%). In only one patient did the skin biopsy add extra diagnostic information. The sensitivity differed between AL and ATTR amyloidosis—81.8% and 41.7%, respectively. Using skin biopsy as the only screening method is not recommended.

ACS Style

Charlotte Hansen; Hanne Møller; Aleksandra Rojek; Niels Marcussen; Hans Beck; Niels Abildgaard. Combined Subcutaneous Fat Aspirate and Skin Tru-Cut Biopsy for Amyloid Screening in Patients with Suspected Systemic Amyloidosis. Molecules 2021, 26, 3649 .

AMA Style

Charlotte Hansen, Hanne Møller, Aleksandra Rojek, Niels Marcussen, Hans Beck, Niels Abildgaard. Combined Subcutaneous Fat Aspirate and Skin Tru-Cut Biopsy for Amyloid Screening in Patients with Suspected Systemic Amyloidosis. Molecules. 2021; 26 (12):3649.

Chicago/Turabian Style

Charlotte Hansen; Hanne Møller; Aleksandra Rojek; Niels Marcussen; Hans Beck; Niels Abildgaard. 2021. "Combined Subcutaneous Fat Aspirate and Skin Tru-Cut Biopsy for Amyloid Screening in Patients with Suspected Systemic Amyloidosis." Molecules 26, no. 12: 3649.

Review
Published: 30 July 2020 in Cancers
Reads 0
Downloads 0

The lytic bone disease is a hallmark of multiple myeloma, being present in about 80% of patients with newly diagnosed MM, and in more during the disease course. The myeloma associated bone disease (MBD) severely affects the morbidity and quality of life of the patients. MBD defines treatment demanding MM. In recent years, knowledge of the underlying pathophysiology has increased, and novel imaging technologies, medical and non-pharmaceutical treatments have improved. In this review, we highlight the major achievements in understanding, diagnosing and treating MBD. For diagnosing MBD, low-dose whole-body CT is now recommended over conventional skeletal survey, but also more advanced functional imaging modalities, such as diffusion-weighted MRI and PET/CT are increasingly important in the assessment and monitoring of MBD. Bisphosphonates have, for many years, played a key role in management of MBD, but denosumab is now an alternative to bisphosphonates, especially in patients with renal impairment. Radiotherapy is used for uncontrolled pain, for impeding fractures and in treatment of impeding or symptomatic spinal cord compression. Cement augmentation has been shown to reduce pain from vertebral compression fractures. Cautious exercise programs are safe and feasible and may have the potential to improve the status of patients with MM.

ACS Style

Stine Rasch; Thomas Lund; Jon Asmussen; Anne Lerberg Nielsen; Rikke Faebo Larsen; Mikkel Østerheden Andersen; Niels Abildgaard. Multiple Myeloma Associated Bone Disease. Cancers 2020, 12, 2113 .

AMA Style

Stine Rasch, Thomas Lund, Jon Asmussen, Anne Lerberg Nielsen, Rikke Faebo Larsen, Mikkel Østerheden Andersen, Niels Abildgaard. Multiple Myeloma Associated Bone Disease. Cancers. 2020; 12 (8):2113.

Chicago/Turabian Style

Stine Rasch; Thomas Lund; Jon Asmussen; Anne Lerberg Nielsen; Rikke Faebo Larsen; Mikkel Østerheden Andersen; Niels Abildgaard. 2020. "Multiple Myeloma Associated Bone Disease." Cancers 12, no. 8: 2113.

Review
Published: 28 January 2019 in Current Oncology Reports
Reads 0
Downloads 0

We discuss current topics on the definition of plasma cell leukemia and the distinction between plasma cell leukemia and multiple myeloma. Moreover, we review the latest literature on how to treat plasma cell leukemia. Plasma cell leukemia is clinically and genetically distinct from multiple myeloma. Plasma cell leukemia is defined by the observation in blood of more than 20% clonal plasma cells by differential count of the leucocytes or by counting more than 2 × 109 per liter circulating clonal plasma cells. However, patients with lower levels of circulating plasma cells have the same adverse prognosis, which challenges the disease definition. Survival has improved after implementation of high-dose chemotherapy with stem-cell support, bortezomib, and lenalidomide in the treatment; yet, the prognosis remains poor. The results of allo-transplants have been disappointing. The diagnostic criteria of PCL are currently discussed in the international myeloma community. Despite some improvement in survival, the prognosis remains adverse. New, more targeted treatment modalities, including immunotherapies, will hopefully improve the outcome in the near future.

ACS Style

Michael Tveden Gundesen; Thomas Lund; Hanne E. H. Moeller; Niels Abildgaard. Plasma Cell Leukemia: Definition, Presentation, and Treatment. Current Oncology Reports 2019, 21, 1 -10.

AMA Style

Michael Tveden Gundesen, Thomas Lund, Hanne E. H. Moeller, Niels Abildgaard. Plasma Cell Leukemia: Definition, Presentation, and Treatment. Current Oncology Reports. 2019; 21 (1):1-10.

Chicago/Turabian Style

Michael Tveden Gundesen; Thomas Lund; Hanne E. H. Moeller; Niels Abildgaard. 2019. "Plasma Cell Leukemia: Definition, Presentation, and Treatment." Current Oncology Reports 21, no. 1: 1-10.

Original article
Published: 19 September 2018 in European Journal of Haematology
Reads 0
Downloads 0

Objectives The Danish Myeloma Study Group initiated a randomized, placebo‐controlled, double‐blinded phase II study to investigate the efficacy of adding clarithromycin to cyclophosphamide‐bortezomib‐dexamethasone (VCD) induction therapy in transplant eligible, newly diagnosed multiple myeloma patients. The study was prematurely terminated due to severe complications, and no effect of adding clarithromycin was found. The aim of this study was to compare health‐related quality of life (HRQoL) between the two groups and to explore the coherence hereof with adverse event (AE) registration by clinicians. Methods Patients completed three validated HRQoL questionnaires at inclusion, before cyclophosphamide priming, and two months after high‐dose therapy (HDT). The mean score difference was interpreted by clinically relevant differences between groups. Spearman correlation analysis was used to compare patient‐reported toxicities with AEs. Results Of 58 included patients, 55 participated in the HRQoL reporting. Before cyclophosphamide priming, patients in the clarithromycin group reported clinically relevant reduced HRQoL for eleven domains with persistent reduction in four domains two months after HDT. Poor correlation between patient‐reported toxicities and clinician‐reported AEs was observed. Conclusions Despite the premature study termination, our data demonstrate impaired HRQoL when clarithromycin was added to the VCD regimen. We found clear underreporting of toxicities by clinicians. ClinicalTrials. gov number NCT02573935. This article is protected by copyright. All rights reserved.

ACS Style

Lene Kongsgaard Nielsen; Tobias Wirenfeldt Klausen; Mary Jarden; Henrik Frederiksen; Annette Juul Vangsted; Trung Do; Ida Bruun Kristensen; Ulf Christian Frølund; Christen Lykkegaard Andersen; Niels Abildgaard; Henrik Gregersen. Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients. European Journal of Haematology 2018, 102, 70 -78.

AMA Style

Lene Kongsgaard Nielsen, Tobias Wirenfeldt Klausen, Mary Jarden, Henrik Frederiksen, Annette Juul Vangsted, Trung Do, Ida Bruun Kristensen, Ulf Christian Frølund, Christen Lykkegaard Andersen, Niels Abildgaard, Henrik Gregersen. Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients. European Journal of Haematology. 2018; 102 (1):70-78.

Chicago/Turabian Style

Lene Kongsgaard Nielsen; Tobias Wirenfeldt Klausen; Mary Jarden; Henrik Frederiksen; Annette Juul Vangsted; Trung Do; Ida Bruun Kristensen; Ulf Christian Frølund; Christen Lykkegaard Andersen; Niels Abildgaard; Henrik Gregersen. 2018. "Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients." European Journal of Haematology 102, no. 1: 70-78.

Journal article
Published: 13 August 2018 in Experimental Hematology & Oncology
Reads 0
Downloads 0

Background The objective of this randomized placebo-controlled study was to investigate the efficacy and safety of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly diagnosed multiple myeloma eligible for high-dose therapy. Methods Patients were randomized to receive tablet clarithromycin 500 mg or matching placebo tablet twice daily during the first 3 cycles of VCD induction therapy. Primary endpoint was to compare the rate of very good partial response (VGPR) or better response after three cycles of VCD combined with clarithromycin or placebo. Results The study was prematurely stopped for safety reasons after the inclusion of 58 patients (36% of the planned study population). The patients were randomly assigned to clarithromycin (n = 27) or placebo (n = 31). VGPR or better response after the VCD induction therapy was obtained in 12 patients (44.4%, 95% CI 25.5–64.7) and in 16 patients (51.6%, 33.1–69.8) (p = 0.59) in the clarithromycin group and the placebo group, respectively. Seven patients (25.9%) in the clarithromycin group developed severe gastrointestinal complications (≥ grade 3) comprising pain, neutropenic enterocolitis, paralytic ileus or peptic ulcer. These complications occurred in only one patient in the placebo group. Septicemia with Gram negative bacteria was observed in 5 patients in the clarithromycin group in contrast to one case of pneumococcal septicemia in the placebo group. Patient-reported QoL were negatively affected in the clarithromycin group compared to the placebo group. Conclusion The study was prematurely stopped due to serious adverse events, in particular serious gastrointestinal complications and septicemia. The response data do not suggest any effect of clarithromycin when added to the VCD regimen. The combination of clarithromycin and bortezomib containing regimens is toxic and do not seem to offer extra anti-myeloma efficacy. Trial registration EudraCT (no. 2014-002187-32, registered 7 October 2014, https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002187-32/DK) and ClinicalTrials.gov (no NCT02573935, retrospectively registered 12 October 2015, https://www.clinicaltrials.gov/ct2/show/NCT02573935?term=Gregersen&cntry=DK&rank=9)

ACS Style

Henrik Gregersen; Trung Do; Ida Bruun Kristensen; Ulf Christian Frølund; Niels Frost Andersen; Lene Kongsgaard Nielsen; Christen Lykkegaard Andersen; Tobias Wirenfeldt Klausen; Annette Juul Vangsted; Niels Abildgaard. A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Experimental Hematology & Oncology 2018, 7, 18 .

AMA Style

Henrik Gregersen, Trung Do, Ida Bruun Kristensen, Ulf Christian Frølund, Niels Frost Andersen, Lene Kongsgaard Nielsen, Christen Lykkegaard Andersen, Tobias Wirenfeldt Klausen, Annette Juul Vangsted, Niels Abildgaard. A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Experimental Hematology & Oncology. 2018; 7 (1):18.

Chicago/Turabian Style

Henrik Gregersen; Trung Do; Ida Bruun Kristensen; Ulf Christian Frølund; Niels Frost Andersen; Lene Kongsgaard Nielsen; Christen Lykkegaard Andersen; Tobias Wirenfeldt Klausen; Annette Juul Vangsted; Niels Abildgaard. 2018. "A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma." Experimental Hematology & Oncology 7, no. 1: 18.

Clinical trial
Published: 06 August 2018 in British Journal of Haematology
Reads 0
Downloads 0

Over the past four decades, remarkable progress has been made in the treatment and prognosis of multiple myeloma (MM), although it remains an incurable disease. Chemotherapy resistance is a major hurdle for treatment efficacy. Drug resistance can be innate and so driven by genes involved in the drug metabolism pathways. We performed an association study of 71 germline variants within the major genes in those pathways (ABCB1, ABCC2, ABCG2, and their regulators NR1I2/PXR and NR1I3/CAR) in the International Multiple Myeloma rESEarch (IMMEnSE) consortium, consisting of 1365 MM cases with survival information recruited in 5 European countries. Two of the SNPs showed a significant association with the survival of MM patients, namely rs2235013, located in ABCB1 [Hazard ratio (HR) = 1·52, 95% confidence interval (CI) = 1·18–1·95, P = 0·00087], and rs4148388, located in ABCC2 (HR = 2·15, 95% CI = 1·44–3·22, P = 0·0001). ABCC2 plays an essential role in transporting various anticancer drugs, including several used against MM, out of the cell. In silico analyses predict that the variant alleles of four SNPs in linkage disequilibrium with ABCC2‐rs4148388 are associated with increased gene expression. Overexpression of ABCC2 increases drug clearance and therefore may induce drug resistance mechanisms. In conclusion, we found a promising association between ABCC2‐rs4148388 and MM outcome that is supported by a plausible biological explanation.

ACS Style

Angelica Macauda; Eleonora Castelli; Gabriele Buda; Matteo Pelosini; Aleksandra Butrym; Marzena Watek; Marcin Kruszewski; Annette Juul Vangsted; Marcin Rymko; Krzysztof Jamroziak; Niels Abildgaard; Eva Kannik Haastrup; Grzegorz Mazur; Rafael Ríos; Artur Jurczyszyn; Daria Zawirska; Marek Dudziński; Małgorzata Raźny; Magdalena Dutka; Waldemar Tomczak; Anna Suska; Agnieszka Druzd-Sitek; Herlander Marques; Mario Petrini; Miroslaw Markiewicz; Joaquin Martinez-Lopez; Lene Hyldahl Ebbesen; Elżbieta Iskierka-Jażdżewska; Juan Sainz; Federico Canzian; Daniele Campa. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. British Journal of Haematology 2018, 183, 375 -384.

AMA Style

Angelica Macauda, Eleonora Castelli, Gabriele Buda, Matteo Pelosini, Aleksandra Butrym, Marzena Watek, Marcin Kruszewski, Annette Juul Vangsted, Marcin Rymko, Krzysztof Jamroziak, Niels Abildgaard, Eva Kannik Haastrup, Grzegorz Mazur, Rafael Ríos, Artur Jurczyszyn, Daria Zawirska, Marek Dudziński, Małgorzata Raźny, Magdalena Dutka, Waldemar Tomczak, Anna Suska, Agnieszka Druzd-Sitek, Herlander Marques, Mario Petrini, Miroslaw Markiewicz, Joaquin Martinez-Lopez, Lene Hyldahl Ebbesen, Elżbieta Iskierka-Jażdżewska, Juan Sainz, Federico Canzian, Daniele Campa. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. British Journal of Haematology. 2018; 183 (3):375-384.

Chicago/Turabian Style

Angelica Macauda; Eleonora Castelli; Gabriele Buda; Matteo Pelosini; Aleksandra Butrym; Marzena Watek; Marcin Kruszewski; Annette Juul Vangsted; Marcin Rymko; Krzysztof Jamroziak; Niels Abildgaard; Eva Kannik Haastrup; Grzegorz Mazur; Rafael Ríos; Artur Jurczyszyn; Daria Zawirska; Marek Dudziński; Małgorzata Raźny; Magdalena Dutka; Waldemar Tomczak; Anna Suska; Agnieszka Druzd-Sitek; Herlander Marques; Mario Petrini; Miroslaw Markiewicz; Joaquin Martinez-Lopez; Lene Hyldahl Ebbesen; Elżbieta Iskierka-Jażdżewska; Juan Sainz; Federico Canzian; Daniele Campa. 2018. "Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients." British Journal of Haematology 183, no. 3: 375-384.

Original article
Published: 12 July 2018 in European Journal of Haematology
Reads 0
Downloads 0

Objective Prognostic and predictive markers in multiple myeloma are continuously explored because of the heterogeneity of the tumor biology. Myc protein is the final product from activating MYC oncogene but the prognostic impact in multiple myeloma is not well described. Methods In a population‐based cohort of 194 untreated, newly diagnosed patients with multiple myeloma, we assessed myc protein expression using CD138/myc immunohistochemical double stain and collected clinicopathological data. Results Cases with myc protein expression ≥40% (mycHIGH) had a median overall survival of 11 months compared to 48 months in cases of myc protein expression <40% (mycLOW) (p<0.01). MycHIGH was significantly correlated to R‐ISS, high proliferation index, high percentage of plasma cell in bone marrow, plasmablastic morphology, high calcium level and abnormal karyotype. In multivariate survival analyses, mycHIGH was independently associated to inferior overall survival with a hazard ratio of 2.5. Conclusion Our results indicate myc protein overexpression to be associated with advanced multiple myeloma and poor prognosis. This article is protected by copyright. All rights reserved.

ACS Style

Hanne Elisabeth Højsgaard Møller; Birgitte S. Preiss; Per Pedersen; Brian Østergaard; Mikael Frederiksen; Niels Abildgaard; Michael B. Møller. Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma. European Journal of Haematology 2018, 101, 585 -590.

AMA Style

Hanne Elisabeth Højsgaard Møller, Birgitte S. Preiss, Per Pedersen, Brian Østergaard, Mikael Frederiksen, Niels Abildgaard, Michael B. Møller. Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma. European Journal of Haematology. 2018; 101 (5):585-590.

Chicago/Turabian Style

Hanne Elisabeth Højsgaard Møller; Birgitte S. Preiss; Per Pedersen; Brian Østergaard; Mikael Frederiksen; Niels Abildgaard; Michael B. Møller. 2018. "Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma." European Journal of Haematology 101, no. 5: 585-590.

Letter to the editor
Published: 14 June 2018 in Biomarker Research
Reads 0
Downloads 0

Chemerin is a recently discovered adipokine shown to be involved in both inflammatory and metabolic processes. Here, we demonstrate that chemerin serum levels are elevated in patients with multiple myeloma and that it increases with disease progression. We found that chemerin is expressed by stromal cells and preadipocytes, whereas its receptor CCRL2 is expressed by primary myeloma cells, suggesting a paracrine signaling loop between bone marrow stromal cells/adipocytes and myeloma cells. This is the first study exploring chemerin and its receptors in multiple myeloma.

ACS Style

Marita Westhrin; Siv Helen Moen; Ida Bruun Kristensen; Glenn Buene; Anne Kærsgaard Mylin; Ingemar Turesson; Niels Abildgaard; Anders Waage; Therese Standal. Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes. Biomarker Research 2018, 6, 21 .

AMA Style

Marita Westhrin, Siv Helen Moen, Ida Bruun Kristensen, Glenn Buene, Anne Kærsgaard Mylin, Ingemar Turesson, Niels Abildgaard, Anders Waage, Therese Standal. Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes. Biomarker Research. 2018; 6 (1):21.

Chicago/Turabian Style

Marita Westhrin; Siv Helen Moen; Ida Bruun Kristensen; Glenn Buene; Anne Kærsgaard Mylin; Ingemar Turesson; Niels Abildgaard; Anders Waage; Therese Standal. 2018. "Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes." Biomarker Research 6, no. 1: 21.

Review
Published: 16 January 2018 in Journal of Hematology & Oncology
Reads 0
Downloads 0

Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography–computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.

ACS Style

J. Caers; B. Paiva; E. Zamagni; X. Leleu; J. Bladé; S. Y. Kristinsson; C. Touzeau; N. Abildgaard; E. Terpos; R. Heusschen; E. Ocio; M. Delforge; O. Sezer; M. Beksac; H. Ludwig; G. Merlini; P. Moreau; S. Zweegman; M. Engelhardt; L. Rosiñol. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology & Oncology 2018, 11, 1 -10.

AMA Style

J. Caers, B. Paiva, E. Zamagni, X. Leleu, J. Bladé, S. Y. Kristinsson, C. Touzeau, N. Abildgaard, E. Terpos, R. Heusschen, E. Ocio, M. Delforge, O. Sezer, M. Beksac, H. Ludwig, G. Merlini, P. Moreau, S. Zweegman, M. Engelhardt, L. Rosiñol. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology & Oncology. 2018; 11 (1):1-10.

Chicago/Turabian Style

J. Caers; B. Paiva; E. Zamagni; X. Leleu; J. Bladé; S. Y. Kristinsson; C. Touzeau; N. Abildgaard; E. Terpos; R. Heusschen; E. Ocio; M. Delforge; O. Sezer; M. Beksac; H. Ludwig; G. Merlini; P. Moreau; S. Zweegman; M. Engelhardt; L. Rosiñol. 2018. "Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel." Journal of Hematology & Oncology 11, no. 1: 1-10.

Research article
Published: 07 December 2017 in PLOS ONE
Reads 0
Downloads 0

Immunoparesis (hypogammaglobulinemia) is associated to an unfavorable prognosis in newly diagnosed Multiple myeloma (MM) patients. However, this finding has not been validated in an unselected population-based cohort. We analyzed 2558 newly diagnosed MM patients in the Danish Multiple Myeloma Registry representing the entire MM population in Denmark from 2005–2013. Two-thousand two hundred and fifty three patients (90%) presented with reduction below lower normal levels of at least one uninvolved immunoglobulin. Using multivariable Cox regression we found that high age, high ISS score, high LDH and IgA MM were associated to both shorter overall survival and progression free survival. Furthermore, bone marrow plasma cell % was associated to short progression free survival. Immunoparesis had no independent significant effect on OS (HR 0.9 (95%CI: 0.7;1.0; p = 0.12)). Likewise, the number of suppressed immunoglobulins or the relative degree of suppressed uninvolved immunoglobulins from lower normal level (quantitative immunoparesis) was not associated to OS in the multivariable analysis. However, quantitative immunoparesis with at least 25% reduction (from lower normal level) of uninvolved immunoglobulins was associated to shorter PFS for the entire population. The impact of quantitative immunoparesis on PFS was present irrespective of calendar periods 2005–2008 and 2009–2013. Our population-based study does not confirm that immunoparesis at diagnosis is an independent prognostic factor regarding OS. However, quantitative immunoparesis is associated to a shorter PFS.

ACS Style

Rasmus Sørrig; Tobias W. Klausen; Morten Salomo; Annette J. Vangsted; Ulf Christian Frølund; Kristian T. Andersen; Anja Klostergaard; Carsten Helleberg; Robert S. Pedersen; Per T. Pedersen; Sissel Helm-Petersen; Elena Manuela Teodorescu; Birgitte Preiss; Niels Abildgaard; Peter Gimsing; for the Danish Myeloma Study Group. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLOS ONE 2017, 12, e0188988 -e0188988.

AMA Style

Rasmus Sørrig, Tobias W. Klausen, Morten Salomo, Annette J. Vangsted, Ulf Christian Frølund, Kristian T. Andersen, Anja Klostergaard, Carsten Helleberg, Robert S. Pedersen, Per T. Pedersen, Sissel Helm-Petersen, Elena Manuela Teodorescu, Birgitte Preiss, Niels Abildgaard, Peter Gimsing, for the Danish Myeloma Study Group. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLOS ONE. 2017; 12 (12):e0188988-e0188988.

Chicago/Turabian Style

Rasmus Sørrig; Tobias W. Klausen; Morten Salomo; Annette J. Vangsted; Ulf Christian Frølund; Kristian T. Andersen; Anja Klostergaard; Carsten Helleberg; Robert S. Pedersen; Per T. Pedersen; Sissel Helm-Petersen; Elena Manuela Teodorescu; Birgitte Preiss; Niels Abildgaard; Peter Gimsing; for the Danish Myeloma Study Group. 2017. "Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population." PLOS ONE 12, no. 12: e0188988-e0188988.

Multicenter study
Published: 29 June 2015 in European Journal of Haematology
Reads 0
Downloads 0

Chromosomal aberrations have significant prognostic importance in multiple myeloma (MM). However, proteasome inhibitors (PI) and IMiDs may partly overcome the poor prognostic impact of some of them. In this study, we investigated a population-based consecutive cohort newly diagnosed patients with MM admitted during a defined time period to hospitals in Denmark, Norway, and Sweden. The impact of treatment modality on the prognostic importance of specific chromosomal aberration was investigated, with special reference to gain 1q21. The median follow-up of patients still alive at analysis was 40 months for the high-dose (HDT)-treated ones and 29 months for the whole population. Three hundred forty-seven patients with a known 1q21 status were included in this study. The 347 patients were divided into three groups, that is, 119 patients with the 1q21 gain, 105 patients with other aberrations (OA), that is, del(13q), del(17p), t(4,14), and/or (14;16), and 123 patients with no aberrations (NA). The groups were compared in terms of overall survival (OS), time to progression (TTP), and response. The 3-yr OS for patients with gain 1q21 was 60% compared to patients with OA 74% and NO 82% (gain 1q21 vs. NO P < 0.001; gain 1q21 vs. OA P = 0.095). If treated with PI or IMiDs, the 3-yr OS was 58% for patients with gain 1q21 compared to patients with OA 78% and NO 78%, respectively (P = 0.041, P = 0.140). In HDT patients, the 3-yr OS was 69% for patients with gain 1q21 compared to patients with OA 84% and NO 88%, respectively (P < 0.008, P = 0.600). Thus, neither HDT nor using PI or IMiDs could overcome the poor prognostic impact of gain 1q21, while these drugs and HDT seemed to improve OS in patients with OA, approaching the survival in NO. Further, gain 1q21 appears to be one of the most important poor prognostic chromosomal aberrations in multiple myeloma with current treatments. Trials using new drugs or allogeneic transplantation are warranted.

ACS Style

Hareth Nahi; Thea Kristin Våtsveen; Johan Lund; Bart M. S. Heeg; Birgitte Preiss; Evren Alici; Michael Boe Møller; Karin Fahl Wader; Hanne E. H. Moller; Lill Anny Grøseth; Brian Østergaard; Hong Yan Dai; Erik Holmberg; Gösta Gahrton; Anders Waage; Niels Abildgaard. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. European Journal of Haematology 2015, 96, 46 -54.

AMA Style

Hareth Nahi, Thea Kristin Våtsveen, Johan Lund, Bart M. S. Heeg, Birgitte Preiss, Evren Alici, Michael Boe Møller, Karin Fahl Wader, Hanne E. H. Moller, Lill Anny Grøseth, Brian Østergaard, Hong Yan Dai, Erik Holmberg, Gösta Gahrton, Anders Waage, Niels Abildgaard. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. European Journal of Haematology. 2015; 96 (1):46-54.

Chicago/Turabian Style

Hareth Nahi; Thea Kristin Våtsveen; Johan Lund; Bart M. S. Heeg; Birgitte Preiss; Evren Alici; Michael Boe Møller; Karin Fahl Wader; Hanne E. H. Moller; Lill Anny Grøseth; Brian Østergaard; Hong Yan Dai; Erik Holmberg; Gösta Gahrton; Anders Waage; Niels Abildgaard. 2015. "Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21." European Journal of Haematology 96, no. 1: 46-54.

Journal article
Published: 02 February 2015 in American Journal of Hematology
Reads 0
Downloads 0
ACS Style

Morten Holmström; Peter Gimsing; Niels Abildgaard; Niels Frost Andersen; Carsten Helleberg; Niels Aage T. Clausen; Tobias W. Klausen; Mikael Frederiksen; Dan L. Kristensen; Herdis Larsen; Per T. Pedersen; Kristian Thidemann Andersen; Robert Schou Pedersen; Bo Amdi Jensen; Henrik Gregersen; Annette J. Vangsted. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. American Journal of Hematology 2015, 90, E73 -E74.

AMA Style

Morten Holmström, Peter Gimsing, Niels Abildgaard, Niels Frost Andersen, Carsten Helleberg, Niels Aage T. Clausen, Tobias W. Klausen, Mikael Frederiksen, Dan L. Kristensen, Herdis Larsen, Per T. Pedersen, Kristian Thidemann Andersen, Robert Schou Pedersen, Bo Amdi Jensen, Henrik Gregersen, Annette J. Vangsted. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. American Journal of Hematology. 2015; 90 (4):E73-E74.

Chicago/Turabian Style

Morten Holmström; Peter Gimsing; Niels Abildgaard; Niels Frost Andersen; Carsten Helleberg; Niels Aage T. Clausen; Tobias W. Klausen; Mikael Frederiksen; Dan L. Kristensen; Herdis Larsen; Per T. Pedersen; Kristian Thidemann Andersen; Robert Schou Pedersen; Bo Amdi Jensen; Henrik Gregersen; Annette J. Vangsted. 2015. "Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database." American Journal of Hematology 90, no. 4: E73-E74.

Journal article
Published: 16 July 2014 in European Journal of Haematology
Reads 0
Downloads 0

In multiple myeloma, heparanase (HSPE) is involved in myeloma cell growth, angiogenesis, osteoclastogenesis and shedding of syndecan-1, a key player in myeloma pathophysiology. Different single nucleotide polymorphisms (SNPs) in the HSPE gene with effect on gene function have been described, and some are associated with haematological malignancies. In this study, we evaluated four SNPs rs11099592, rs4364254, rs4693608 and rs6535455 in the HSPE gene in 348 newly diagnosed multiple myeloma patients with focus on bone morbidity (lytic bone disease and vertebral fractures) and outcome after high-dose chemotherapy with stem cell support (HDT). We observed that homozygous carriers of the rs4693608 wild-type A-allele had a higher frequency of vertebral fractures compared to carriers of the variant G-allele, P = 0.02. In multivariate analysis, homozygous carriers of the rs6535455 variant T-allele had a longer survival than homo- and heterozygous carriers of the wild-type C-allele, hazard ratio 0.3 (95% CI 0.1-0.7, P = 0.002). The SNPs rs4693608 and rs6535455 in the HSPE gene may influence bone morbidity and outcome in multiple myeloma. Our results are an interesting observation but can be chance findings and need confirmation in studies exploring the functional role of SNPs in the HSPE gene in multiple myeloma.

ACS Style

Niels F. Andersen; Ulla Vogel; Tobias W. Klausen; Peter Gimsing; Henrik Gregersen; Niels Abildgaard; Annette Juul Vangsted. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival. European Journal of Haematology 2014, 94, 60 -66.

AMA Style

Niels F. Andersen, Ulla Vogel, Tobias W. Klausen, Peter Gimsing, Henrik Gregersen, Niels Abildgaard, Annette Juul Vangsted. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival. European Journal of Haematology. 2014; 94 (1):60-66.

Chicago/Turabian Style

Niels F. Andersen; Ulla Vogel; Tobias W. Klausen; Peter Gimsing; Henrik Gregersen; Niels Abildgaard; Annette Juul Vangsted. 2014. "Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival." European Journal of Haematology 94, no. 1: 60-66.

Journal article
Published: 17 May 2014 in European Journal of Haematology
Reads 0
Downloads 0
ACS Style

Annette Juul Vangsted; Tobias W. Klausen; Peter Gimsing; Niels Abildgaard; Niels F. Andersen; Anne O. Gang; Morten Holmström; Henrik Gregersen; Ulla Vogel; Peter Schwarz; Niklas Rye Jørgensen. Genetic variants in theP2RX7gene are associated with risk of multiple myeloma. European Journal of Haematology 2014, 93, 172 -174.

AMA Style

Annette Juul Vangsted, Tobias W. Klausen, Peter Gimsing, Niels Abildgaard, Niels F. Andersen, Anne O. Gang, Morten Holmström, Henrik Gregersen, Ulla Vogel, Peter Schwarz, Niklas Rye Jørgensen. Genetic variants in theP2RX7gene are associated with risk of multiple myeloma. European Journal of Haematology. 2014; 93 (2):172-174.

Chicago/Turabian Style

Annette Juul Vangsted; Tobias W. Klausen; Peter Gimsing; Niels Abildgaard; Niels F. Andersen; Anne O. Gang; Morten Holmström; Henrik Gregersen; Ulla Vogel; Peter Schwarz; Niklas Rye Jørgensen. 2014. "Genetic variants in theP2RX7gene are associated with risk of multiple myeloma." European Journal of Haematology 93, no. 2: 172-174.

Journal article
Published: 05 January 2009 in Ugeskrift for laeger
Reads 0
Downloads 0
ACS Style

Thomas Lund; Henrik Gregersen; Annette Vangsted; Peter Marker; Niels Abildgaard. [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. Ugeskrift for laeger 2009, 171, 1 .

AMA Style

Thomas Lund, Henrik Gregersen, Annette Vangsted, Peter Marker, Niels Abildgaard. [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. Ugeskrift for laeger. 2009; 171 (1):1.

Chicago/Turabian Style

Thomas Lund; Henrik Gregersen; Annette Vangsted; Peter Marker; Niels Abildgaard. 2009. "[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]." Ugeskrift for laeger 171, no. 1: 1.